Evidence map›Paper›PMID 40072469›Full record

ArticleCancer immunology research2025

IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma.

Zoe C Schmiechen, Hezkiel A Nanda, Adam L Burrack, Grant H Hickok, Jonah Z Butler, Eduardo Cruz-Hinojoza, Nicholas J Maurice, Michael J Geuenich, Chengxin Yu, Alexander K Tsai and 9 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zoe C SchmiechenCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0002-3403-6824
Hezkiel A NandaInstitute for Health Informatics, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0003-1406-1659
Adam L BurrackCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0002-4001-7849
Grant H HickokCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0009-0004-8235-4773
Jonah Z ButlerCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0002-8694-7590
Eduardo Cruz-HinojozaCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0003-3279-133X
Nicholas J MauriceCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0002-2667-472X
Michael J GeuenichLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.ORCID 0009-0001-8211-3070
Chengxin YuLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.ORCID 0000-0002-0319-8839
Alexander K TsaiCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0002-4014-1946
Cara-Lin LonetreeCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0002-2760-8572
Madeline A EllefsonCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0009-0005-7613-0404
Audrey L HilkCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0009-0004-4402-8395
Brandon M LarsenCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0009-0003-5647-3202
Ebony A Miller *Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.
Antonio B RizzoCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0009-0005-7272-8038
Kieran R CampbellLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.ORCID 0000-0003-1981-5763
Steven S ShenInstitute for Health Informatics, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0001-7725-1260
Ingunn M StromnesCenter for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota.ORCID 0000-0001-8120-4547

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Project 3P01CA254849 · NCI · UNIVERSITY OF MINNESOTA · PI ODDE, DAVID J. · 2021 to 2025
$9.4M
TECH CoreU54CA268069 · NCI · UNIVERSITY OF MINNESOTA · PI David J. Odde · 2022 to 2026
$8.2M
Training Grant: Functional Proteomics of AgingT32AG029796 · NIA · UNIVERSITY OF MINNESOTA · PI EDGAR A ARRIAGA, Douglas G Mashek · 2008 to 2026
$6.6M
IMMUNOLOGY TRAINING PROGRAMT32AI007313 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Carla Rothlin · 1989 to 2026
$5.7M
Epigenetic Mechanisms Promoting LongevityR01AG054840 · NIA · DUKE UNIVERSITY · PI KRAUS, VIRGINIA · 2018 to 2022
$3.4M
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinomaR01CA249393 · NCI · UNIVERSITY OF MINNESOTA · PI STROMNES, INGUNN MARGARETE · 2021 to 2025
$2.1M
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinomaR01CA255039 · NCI · UNIVERSITY OF MINNESOTA · PI STROMNES, INGUNN MARGARETE · 2021 to 2025
$2.0M
Profiling and leveraging bystander T cells within the tumor microenvironmentK00CA245735 · NCI · UNIVERSITY OF MINNESOTA · PI MAURICE, NICHOLAS JOSEPH · 2022 to 2025
$372k
Medical Student Summer Research Program in Infection and ImmunityT35AI118620 · NIAID · UNIVERSITY OF MINNESOTA · PI MUELLER, DANIEL L · 2015 to 2025
$351k
Elucidating the Role of Tregs in Cancer Metastasis and T Cell DysfunctionF31CA275289 · NCI · UNIVERSITY OF MINNESOTA · PI SCHMIECHEN, ZOE · 2023 to 2024
$67k
American Cancer Society (ACS) RSG-21-102-01-IBCDCanadian Institutes of Health Research (CIHR) PJT-175270Congressionally Directed Medical Research Programs (CDMRP) W81XWH2110525National Institutes of Health (NIH) 1UL1TR002494-01National Institutes of Health (NIH) F31CA275289National Institutes of Health (NIH) K00CA245735National Institutes of Health (NIH) P01CA254849National Institutes of Health (NIH) R01AG054840-01A1National Institutes of Health (NIH) R01CA249393National Institutes of Health (NIH) R01CA255039National Institutes of Health (NIH) T32AI007313National Institutes of Health (NIH) T32CA009138-48National Institutes of Health (NIH) T35AI118620National Institutes of Health (NIH) U54CA268069Natural Sciences and Engineering Research Council of Canada (NSERC) 04083Natural Sciences and Engineering Research Council of Canada (NSERC) RGPIN-2020-NCATS NIH HHS UL1 TR002494NCI NIH HHS F31 CA275289NCI NIH HHS K00 CA245735NCI NIH HHS P01 CA254849NCI NIH HHS R01 CA249393NCI NIH HHS R01 CA255039NCI NIH HHS T32 CA009138NCI NIH HHS U54 CA268069NIAID NIH HHS T32 AI007313NIAID NIH HHS T35 AI118620NIA NIH HHS R01 AG054840NIA NIH HHS T32 AG029796Pancreatic Cancer Action Network (PCAN) 19-35-STRO
6 · The paper itself

Abstract

Agonistic anti-CD40 with anti-PD-1 can elicit objective responses in a small number of patients with pancreatic ductal adenocarcinoma (PDA). Better understanding of their individual effects on the pancreatic tumor microenvironment will help inform new strategies to further improve outcomes. In this study, we map tumor-specific CD8+ T-cell differentiation following agonistic anti-CD40 and/or anti-PDL1 in PDA. Rare Tcf1+Slamf6+ tumor-specific CD8+ T cells are identified and likely seed memory precursors that transition into exhausted or effector T cells. In tumors, anti-PDL1 drove the clonal expansion of Gzmk+ progenitor exhausted CD8+ T cells, whereas anti-CD40 promoted CD4+ T-cell clonal expansion and accumulation of Tcf1+Slamf6+ CD8+ T cells. Cloning the most frequent intratumoral T-cell receptors revealed identical neoepitope specificity, yet the top T-cell receptors from anti-PDL1 ± anti-CD40 cohorts lacked tetramer binding, suggesting lower affinity. Anti-CD40 + anti-PDL1 markedly drove the clonal hyperexpansion of a unique exhausted T-cell subset in the spleen. Exhausted T cells were enriched for IL-2Rβ, and provision of IL-15 complex (IL-15C) mitigated systemic and intratumoral T-cell exhaustion when combined with anti-CD40 + anti-PDL1, resulting in enhanced antitumor effects, prolongation of animal survival, and resistance to orthotopic tumor rechallenge. Mechanistically, anti-CD40 + anti-PDL1 decreased Tox, whereas IL-15C + anti-CD40 + anti-PDL1 increased T-bet, thereby conferring a higher T-bet:Tox ratio in tumor-specific CD8+ T cells. Collectively, agonistic anti-CD40 + anti-PDL1 drove systemic and intratumoral CD8+ T-cell clonal expansion and acquisition of exhaustion features in a tissue-specific manner. Provision of IL-15C altered the trajectory of T-cell differentiation induced by immunotherapy, resulting in PDA eradication and long-lived antitumor memory T cells.

Indexed as

B7-H1 AntigenCarcinoma, Pancreatic DuctalCD40 AntigensCD8-Positive T-LymphocytesInterleukin-15Lymphocytes, Tumor-InfiltratingPancreatic NeoplasmsT-Box Domain ProteinsAnimalsCell Line, TumorFemaleHumansMiceT-bet Transcription FactorTumor MicroenvironmentB7-H1 AntigenCD274 protein, humanCD40 AntigensInterleukin-15T-bet Transcription FactorT-Box Domain Proteins

Identifiers

PMID40072469
PMCPMC12134750

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.